MoneyWorks4Me

Lupin gets EIR from USFDA for inspection of its Nagpur facility

24 Aug 2018 Evaluate

Lupin has received the Establishment Investigation Report (EIR) from US Food and Drug Administration (USFDA) for the successful inspection of its Nagpur facility. The inspection was conducted in May 2018. The successful completion of the Nagpur facility inspection is a positive development as the company continues to meet and exceed international regulatory standards.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..